What GenKardia does

GenKardia Inc. is a privately held, research-stage biotechnology company founded in 2022 and headquartered at 27 E 28th Street, New York, NY. It develops RNA-based therapeutic strategies intended to inhibit and reverse the development and progression of heart failure by targeting the molecular mechanisms of cardiac muscle pathology rather than addressing symptoms. The pipeline currently comprises two RNA-based programs targeting two distinct molecular mechanisms, supported by foundational intellectual property, and positioned for a population the company sizes at 7 million Americans and 60 million patients worldwide with a cited 50% five-year mortality rate.

The company is led by Founder and CEO David C. Zebrowski, Ph.D. (formerly of AstraZeneca, Novo Nordisk, Harvard Medical School, and the Max Planck Institute) together with Co-Founder and Chief Development Officer Richard Nkulikiyinka, MB BChir (former VP and Head of Therapeutic Area Cardiology at Bayer, where he oversaw Phase III and NDA programs for vericiguat and finerenone), and Co-Founder and VP, Head of Translational Science Sandor Batkai, M.D., Ph.D. (co-founder of Cardior Pharmaceuticals, acquired by Novo Nordisk in 2024). GenKardia has assembled a Scientific Advisory Board of senior cardiovascular KOLs (Wolfgang Linke, Rong Tian, Michael Zile, David A. Kass) and RNAi advisors (Julia Alterman, Marc Lamaitre), and lists external collaborators including ADViRNA as CRO and Jonathan Kirk, Ph.D. at the University of Chicago as a Strategic Partner.

GenKardia's only disclosed financing to date is a $250,000 XSEED award granted in May 2025 by CURE., Deerfield Management, and NYCEDC to support minority and women-led drug development startups. The company has no commercial product, no disclosed customers, no published pricing, and no out-licensing or partnership economics in the source materials; revenue model is effectively absent until a product or partnership enters commercialization. The GTM posture is therefore preclinical pipeline development, with future distribution assumed to occur via regulatory approval and/or pharmaceutical partnerships.

Name

GenKardia

Legal name

GenKardia Inc.

Website

https://genkardia.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

GenKardia Inc. is a New York-based, pre-revenue biotech founded in 2022 developing RNA-based therapeutics aimed at the molecular causes of cardiac muscle pathology in heart failure. It targets heart failure patients globally via two preclinical RNA programs supported by foundational IP.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels2 records

Core offering

GenKardia is a research-stage biotech company developing an RNA-based therapeutic pipeline targeting heart failure. The pipeline consists of two RNA-based therapeutic strategies, supported by strong foundational IP, that inhibit and reverse heart failure development and progression by addressing the core molecular underpinnings of cardiac muscle pathology rather than only managing symptoms. The company does not yet have any commercialized products and operates in pre-clinical / pipeline development stage.

Product overview

GenKardia is a biotech company developing novel therapeutics for heart failure. Their pipeline consists of two RNA-based therapeutic strategies targeting unique molecular mechanisms in cardiac muscle pathology. The company operates as a research-stage pharmaceutical developer focused on addressing the core underpinnings of heart failure rather than just managing symptoms.

Differentiator

Problem solved

Functional benefit

Products and services

• RNA-Based Therapeutic Pipeline for Heart Failure GenKardia's pipeline consists of two RNA-based therapeutic strategies targeting heart failure through two unique molecular mechanisms, supported by strong foundational IP. The candidates are designed to inhibit and reverse heart failure development and progression by addressing the core molecular underpinnings of cardiac muscle pathology, rather than only managing symptoms. The pipeline is in pre-clinical / research-stage development and is not yet commercialized; ultimate end users will be heart failure patients, with current commercial engagement directed at pharmaceutical partners and CROs.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• University of Chicago (Jonathan Kirk, Ph.D.)minorStrategic or Co-development PartnerJonathan Kirk, Ph.D. from University of Chicago is listed as a strategic partner, providing academic collaboration and expertise in cardiovascular research.

Recent moves5 records

Expansion highlights5 records

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genkardia

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenKardia